“…Hitherto, the clinical benefit for the patient is unclear. Actually, all retrieved randomised phase III studies but one [31] were designed with a superiority hypothesis for median survival [19,24,25], 1-year survival [20,29,30], progression-free survival [32,33] or quality of life [21] in favour of the non-platinum regimens. The statistical design is unknown in two cases [22,26].…”